TENAX THERAPEUTICS, INC. — Form 8-K
Filed October 8, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
Tenax's Phase 3 LEVEL trial of oral levosimendan (TNX-103) in PH-HFpEF missed its primary endpoint of 6-minute walk distance (6MWD) change in the overall population (3.5 m vs placebo, p=0.63, N=241). However, post-hoc analysis identified a strong treatment effect in the sicker subgroup: patients with baseline 6MWD ≤333 m showed +26.3 m improvement vs placebo (95% CI: 6.0–46.7 m; p=0.0112). Tenax is amending LEVEL-2 protocol to enrich for this population and pausing enrollment temporarily for FDA engagement. NT-proBNP fell 49% on levosimendan (p=0.0001). Cash runway extended through Q2 2028.
Why this rating
Trial missed primary endpoint, eroding regulatory confidence. Enrichment strategy is post-hoc and requires FDA approval—clinical/regulatory risk remains material. However, biologics validated, cash extended. For $23.8M-cap company, protocol amendment and re-enrollment delay are significant setbacks, but not fatal if enrichment succeeds.
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.